In terms of innovation, according to the "2021 National Blue Book of Chinese Medicine Supervision" released in July, in 2021, China approved the listing of 12 new Chinese medicine drugs, and
the number has exceeded the sum of the past four years.
According to the CDE Catalogue of Accepted Varieties, the innovative achievements of Traditional Chinese medicines in 2022 are still accelerating, and from January to March, CDE has undertaken to accept 18 applications for
the registration of new Chinese medicines.
The types of new Chinese medicine drugs applied for focus on class 1.
1 and class 1.
2, of which there are 6 new drugs in class 1.
1
.
Traditional Chinese medicine enterprises accelerate transformation and upgrading, and the development trend of diversification is clear (Source: Pharmaceutical Network)
At present, while the development of the Chinese medicine industry is improving, a large number of Chinese medicine companies are adjusting and upgrading
their development strategies.
For example, in the business of traditional Chinese medicine formula granules, CR Sanjiu is increasing the number of products by strengthening the construction of medicinal material planting bases and the research on the origin of medicinal materials, and relying on intelligent Chinese medicine pharmacies for business promotion, so as to promote the rapid growth
of the business with the overall ability of the industrial chain.
In fact, under the background of the normalization of traditional Chinese medicine collection and the increased risk of product price decline brought about by the expansion of the scope of implementation, many enterprises are making strategic adjustments
through innovation in order to obtain lasting development momentum.
For example, Guangyao Baiyun Mountain insists on "self-research + cooperation" to walk
on two legs.
At present, it has more than 10 new drug projects in the research of class 1, covering cardiovascular and cerebrovascular diseases, anti-tumor drugs, vaccines and other fields
.
Of the 2 new drugs of Class 1 declared, cefozime sodium has entered the clinical phase I stage, and BYS10 tablets have been approved for clinical trials
.
In addition, many Chinese medicine enterprises are also making efforts
in the fields of biological drugs and chemical drugs through innovative research and development.
Companies such as Tasly, Jiuzhitang, Zhongsheng Pharmaceutical, Yuheng Pharmaceutical and other companies are targeting small molecule chemical drugs and even monoclonal antibodies, double antibodies, cell therapy, and even PD-1, CAR-T and other popular biological drug layouts
in recent years.
It is worth mentioning that in recent years, in many strategic adjustment directions, the field of big health is particularly favored
by traditional Chinese medicine enterprises.
For example, Katazai has already made moves in the field of great health, on October 24, 2020, Katazai issued an announcement that it is ready to divest its Fujian Katazai Cosmetics Co.
, Ltd.
and achieve a separate listing
.
In recent years, Liuyao Group is also accelerating its industrial layout around the health industry of traditional Chinese medicine, and at present, the company's Wantong Pharmaceutical has national exclusive products such as Wantong Yankang Tablets and Compound Money Grass, and has carried out new product development
including Angong Niuhuang Pill, Liuwei Pill and Damp Jian Spleen Tea.
In addition, its Subsidiary Kangsheng Pharmaceutical has guiqi blood replenishment oral liquid, tranquility blood nourishing oral liquid and other brands.
.
.
.
.
.
At present, the company is also accelerating the development of supporting industries such as chinese medicine decoction and traditional Chinese medicine clinics, and gradually realizing the chinese medicine health industry system
covering the whole industrial chain of traditional Chinese medicine planting and harvesting, production and processing, logistics and trade, terminal application, etc.
Yiling Pharmaceutical also began to lay out the big health industry a few years ago, and its efforts to build Ling Health Technology Co.
, Ltd.
to "tongluo - yangjing - moving - jingshen" health care eight characters as the cultural leadership, fully excavate the theoretical essence of traditional Chinese health care, adhering to the concept of traditional Chinese medicine to treat the pathology, integration of modern science and technology, carry out multi-faceted health product research and development and health management services, and establish a health industry system
that integrates "medicine, medicine, health, and health", combining online and offline.
On the whole, in the traditional Chinese medicine industry, the wind of transformation and upgrading of pharmaceutical companies has not stopped
.
According to the current development trend, industry analysis believes that in the future, the entire Chinese medicine industry will show a diversified development trend, and all Chinese medicine enterprises will be roughly divided into three categories: First, to become an enterprise that relies on existing advantages and through continuous transformation, the future daily chemical products and other business income will exceed the income of
traditional Chinese medicine.
The second is to continue to deepen the field of traditional Chinese medicine, diligently and earnestly conduct evidence-based research on listed drugs, and chinese medicine enterprises with important clinical value products
.
The third is to adhere to the innovation and development of traditional Chinese medicine while expanding other pharmaceutical fields and becoming an enterprise for the common development of Chinese and Western medicine.
